Literature DB >> 32725436

Effects of Yoga-Based Interventions on Cancer-Associated Cognitive Decline: a Systematic Review.

Mohamad Baydoun1, Devesh Oberoi1, Michelle Flynn2, Chelsea Moran2, Andrew McLennan1, Katherine-Ann L Piedalue1, Linda E Carlson3.   

Abstract

PURPOSE OF REVIEW: To summarize and evaluate evidence available on the effects of yoga on cancer-associated cognitive decline (CACD). RECENT
FINDINGS: A systematic review was conducted using four databases of articles published before January 1, 2020. Ten articles met the inclusion criteria (six randomized controlled trials, two single-arm studies, one non-randomized controlled trial, and one case series study). Studies were predominantly conducted with breast cancer patients using low-intensity hatha yoga programs. Of the 10 articles, five reported some positive effects on CACD, but significant biases were possible due to design shortcomings. Cohen's d effect sizes ranged from |0.03| to |0.74|. The evidence to date is insufficient to suggest that yoga is beneficial for attenuating CACD. More rigorous trials controlling for non-specific factors are warranted. The field would also benefit from examining self-delivered modes of yoga for treating CACD in various cancer populations to enhance practice sustainability and generalizability.

Entities:  

Keywords:  Breast cancer; Cancer; Cancer-associated cognitive decline; Complementary therapies; Integrative oncology; Psycho-oncology; Yoga

Year:  2020        PMID: 32725436     DOI: 10.1007/s11912-020-00960-5

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  1 in total

1.  Effects of Vigorous Versus Restorative Yoga Practice on Objective Cognition Functions in Sedentary Breast and Ovarian Cancer Survivors: A Randomized Controlled Pilot Trial.

Authors:  Gary Deng; Ting Bao; Elizabeth L Ryan; Lara Benusis; Pasha Hogan; Qing S Li; Annika Dries; Jason Konner; Tim A Ahles; Jun J Mao
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.077

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.